SB 606-FN (2026): relative to insurance coverage for biomarker testing.

SB 606-FN (2026)

relative to insurance coverage for biomarker testing.

• Status: Referred for interim study
• Term: 2025-2026
• House committee: Commerce and Consumer Affairs
• Senate committee: Health and Human Services
• Subject: Insurance

The Story

It was introduced on January 7, 2026 and referred to the Senate Health and Human Services committee. The committee held a public hearing on January 28, 2026. The committee voted unanimously, 5–0, to recommend that the Senate pass it with changes (amendment 2026-0689s), and the report was placed on the consent calendar. The committee's amendment (2026-0689s) was adopted on a voice vote on February 19, 2026, changing the text of the bill. On February 19, 2026 the Senate voted to pass it with changes on a voice vote, then referred it on to the Senate Finance committee. The committee voted unanimously, 7–0, to recommend that the Senate pass it, and the report was placed on the consent calendar. On March 12, 2026 the Senate voted to pass it on a voice vote and ordered it to a third reading. It crossed to the House on March 12, 2026 and was referred to the House Commerce and Consumer Affairs committee. The committee held a public hearing on April 1, 2026, with 19 people signed in online: 18 in support and 1 as neutral. The committee held work sessions on April 8, 2026, April 22, 2026 and April 28, 2026. The committee met in executive session on April 29, 2026 to vote on its recommendation. The committee voted unanimously, 15–0, to recommend that the House study it after the session ends, and the report was placed on the consent calendar. On May 14, 2026 the House voted to study it after the session ends on a voice vote. The committee held a work session on September 9, 2026. The committee met in executive session on October 14, 2026 to vote on its recommendation. On October 15, 2026 the committee reported back on its interim study of the bill: “Not Recommended for Future Legislation”, by a vote of 11 to 0.

Sponsors

• Sen. Regina Birdsell (R - SD19) (prime sponsor)
• Sen. Daniel Innis (R - SD7)

Hearings and Sessions

• January 28, 2026, 9:00 AM: hearing, Senate Health and Human Services, SH 100
• February 19, 2026: consent calendar, Senate
• March 12, 2026: consent calendar, Senate
• April 1, 2026, 11:00 AM: public hearing, House Commerce and Consumer Affairs, GP 229
• April 8, 2026, 10:00 AM: subcommittee work session, House Commerce and Consumer Affairs, GP 229
• April 22, 2026, 10:00 AM: subcommittee work session, House Commerce and Consumer Affairs, GP 229
• April 28, 2026, 10:00 AM: subcommittee work session, House Commerce and Consumer Affairs, GP 229
• April 29, 2026, 10:00 AM: executive session, House Commerce and Consumer Affairs, GP 229
• May 14, 2026: floor debate, House
• September 9, 2026, 10:00 AM: subcommittee work session, House Commerce and Consumer Affairs, GP 229
• October 14, 2026, 10:00 AM: executive session, House Commerce and Consumer Affairs, GP 229

Votes

• February 19, 2026, Senate: Ought to Pass with Amendment #2026-0689s — voice vote, passed
• March 12, 2026, Senate: Ought to Pass — voice vote, passed
• May 14, 2026, House: Refer for Interim Study — voice vote, passed

The Docket

Laws It Would Change

• RSA 420-J
• RSA 167

Related Bills

• HB 2-FN-A-LOCAL (2025): relative to state fees, funds, revenues, and expenditures.
• SB 120-FN (2025): relative to insurance coverage for biomarker testing.
• SB 120-FN (2025): relative to insurance coverage for biomarker testing.

From the General Court

• Bill text
• Bill status page
• Docket
• SJ 1
• SC 3
• SC 6
• SJ 4
• SC 9
• SJ 6
• HJ 8, page 114
• HC 19, page 8
• HJ 13, page 9